A UK COST-UTILITY ANALYSIS OF FERRIC CARBOXYMALTOSE VERSUS FERRIC DERISOMALTOSE IN PATIENTS WITH IRON DEFICIENCY ANEMIA AND INFLAMMATORY BOWEL DISEASE: INCORPORATION OF FRACTURE DATA

被引：0
|
作者：
Zoller, H. [1 ]
Pammer, L. M. [1 ]
Nottmeier, M. [2 ]
Poehlmann, J. [3 ]
Pollock, R. F. [3 ]
机构：
[1] Med Univ Innsbruck, Innsbruck, Austria
[2] Pharmacosmos AS, Ballerup 84, Denmark
[3] Covalence Res Ltd, Harpenden, Herts, England
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE68
引用
收藏
页码：S69 / S70
页数：2
相关论文
共 50 条
  • [41] Ferric Carboxymaltose Improves the Quality of Life of Patients with Inflammatory Bowel Disease and Iron Deficiency without Anaemia
    Maria Huguet, Jose
    Cortes, Xavier
    Maia Bosca-Watts, Marta
    Munoz, Margarita
    Maroto, Nuria
    Iborra, Marisa
    Hinojosa, Esther
    Capilla, Maria
    Asencio, Carmina
    Amoros, Cirilo
    Maria Paredes, Jose
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (10)
  • [42] Iron Status and Analysis of Efficacy and Safety of Ferric Carboxymaltose Treatment in Patients with Inflammatory Bowel Disease
    Beigel, Florian
    Loehr, Beate
    Laubender, Ruediger P.
    Tillack, Cornelia
    Schnitzler, Fabian
    Breiteneicher, Simone
    Weidinger, Maria
    Goeke, Burkhard
    Seiderer, Julia
    Ochsenkuehn, Thomas
    Brand, Stephan
    DIGESTION, 2012, 85 (01) : 47 - 54
  • [43] Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency Anemia
    Hussain, Iftikhar
    Bhoyroo, Jessica
    Butcher, Angelia
    Koch, Todd A.
    He, Andy
    Bregman, David B.
    ANEMIA, 2013, 2013
  • [44] Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside
    Detlie, Trond Espen
    Lindstrom, Jonas Christoffer
    Jahnsen, Marte Eide
    Finnes, Elisabeth
    Zoller, Heinz
    Moum, Bjorn
    Jahnsen, Jorgen
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 50 (04) : 397 - 406
  • [45] COST-EFFECTIVENESS ANALYSIS OF FERRIC MALTOL VERSUS FERRIC CARBOXYMALTOSE FOR THE TREATMENT OF IRON DEFICIENCY ANAEMIA IN IBD PATIENTS IN SWEDEN AND FINLAND
    Hjelmgren, J.
    Ericson, O.
    Niska, P.
    Kukkonen, P.
    Birgegard, G.
    VALUE IN HEALTH, 2018, 21 : S452 - S453
  • [46] Efficacy and Safety of Ferric Derisomaltose/Iron Isomaltoside in Patients with Inflammatory Bowel Disease: A Systematic Review
    Sam, Keren
    Khan, Atif Irfan
    Khan, Anam
    Aamir, Sobia
    Sajid, Fatima
    Nasir, Yusra Minahil
    Arslan, Muhammad
    Asad, Muhammad
    Anwer, Faiz
    BLOOD, 2021, 138
  • [47] Anemia and iron deficiency in inflammatory bowel disease: an open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life
    Befrits, Ragnar
    Wikman, Ola
    Blomquist, Lars
    Hjortswang, Henrik
    Hammarlund, Per
    Bajor, Antal
    Klintman, Daniel
    Blom, Hakan
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2013, 48 (09) : 1027 - 1032
  • [48] Ironing Out the Efficacy and Safety Profile of Ferric Carboxymaltose Infusions for the Treatment of Iron Deficiency and Iron-Deficiency Anemia in Pediatric Inflammatory Bowel Disease
    Quake, Christine
    Albenberg, Lindsey
    Baldassano, Robert
    Breton, Jessica
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (12S): : S15 - S16
  • [49] Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice
    Stein, Juergen
    Aksan, Ayseguel
    Klemm, Wolfgang
    Nip, Kerry
    Weber-Mangal, Susanne
    Dignass, Axel
    JOURNAL OF CROHNS & COLITIS, 2018, 12 (07): : 826 - 834
  • [50] TREATMENT OF IRON DEFICIENCY WITHOUT ANEMIA WITH FERRIC CARBOXYMALTOSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: PROSPECTIVE EVALUATION OF CLINICAL AND PATIENT-REPORTED OUTCOMES IN SPAIN
    Huguet, J. M.
    Paredes, J. M.
    Cortes, X.
    Maorto, N.
    Bosca-Watts, M. M.
    Hinojosa, E.
    Iborra, M.
    Amoros, C.
    Munoz, M.
    VALUE IN HEALTH, 2022, 25 (01) : S241 - S241
12345